[Prevention of embolic heart complications in atrial fibrillation: possibilities of using rivaroxaban].

The review analyzes the role of atrial fibrillation concurrent with stable manifestations of coronary heart disease when novel oral anticoagulants are used. It gives the results of comparison of the efficacy and safety of warfarin and rivaroxaban in such patients in the large controlled ROCKET-AF trial.

[Peculiarities of antithrombotic treatment in exacerbation of coronary heart disease and transcutaneous coronary interventions in patients suffering from atrial fibrillation and taking vitamin K antagonists (literature review)].

The review analyses various approaches to management of patients presenting with atrial fibrillation and having to take vitamin K agonists in order to prevent arterial thromboembolic complications in cases they develop exacerbations of their coronary hear disease and/or require transcutaneous coronary interventions. With the problem being insufficiently studied as yet, the majority of therapeutic decisions as to the most efficient and safe methods of administering antithrombotic agents in the clinical situations involved are made based on the results of follow up of the patients, the data regarding peculiarities of the action of therapeutic agents, and common sense. Presented herein are contemporary recommendations on long-term antithrombotic therapy in patients suffering from atrial fibrillation and taking vitamin K antagonists and subjected to coronary stenting.

[Disputable issues of anticoagulant therapy: exacerbation of coronary heart disease and transcutaneous interventions in patients with cardiac fibrillation treated with vitamin K antagonists].

The article concerns the policy of anti-platelet treatment in patients with coronary heart disease exposed to transcutaneous coronary interventions. Patients with cardiac fibrillations are specially considered. International trials are reviewed.